Compugen Ltd. Closes Public Offering of Ordinary Shares
March 05 2014 - 4:05PM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today
announced that it has closed its underwritten public offering of
6,900,000 ordinary shares, including 900,000 shares sold pursuant
to the full exercise of the underwriters’ option to purchase
additional shares, at a price to the public of $10.50 per share.
Gross proceeds to Compugen are approximately $72.5 million, before
deducting the underwriting discounts and commissions and estimated
offering expenses payable by Compugen.
Jefferies LLC acted as the sole bookrunner for the proposed
offering. JMP Securities LLC, Oppenheimer & Co. Inc. and
Chardan Capital Markets acted as co-managers.
A shelf registration statement on Form F-3 relating to the
public offering of the ordinary shares described above has been
filed with the Securities and Exchange Commission (the “SEC”) and
is effective. A final prospectus supplement relating to the
offering has been filed with the SEC and is available on the SEC’s
website at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to this
offering may also be obtained from Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor,
New York, NY, 10022, by telephone at 877-547-6340, or by email at
Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The Company
utilizes a broad and continuously growing integrated infrastructure
of proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer) prediction and
selection of product candidates, which are then advanced in its
Pipeline Program. The Company's business model includes
collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. In 2012, Compugen established operations in
California for the development of oncology and immunology
monoclonal antibody therapeutic candidates against Compugen drug
targets.
Forward-looking Statements
Certain of the statements made in this press release are forward
looking. Actual results or developments may differ materially from
those projected or implied in these forward looking statements.
Such statements are based on assumptions and subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by such forward-looking statements,
including those described in "Risk Factors" of the final prospectus
supplement related to the offering, as filed with the SEC. In
addition, the forward-looking statements included in this press
release represent our views as of the date of this press release.
We anticipate that subsequent events and developments will cause
our views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Compugen Ltd.Tsipi HaitovskyGlobal Media LiaisonEmail:
tsipih@netvision.net.ilTel: +972-52-598-9892
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024